DCZ19931_product_DataBase

Bioactivity	DCZ19931 is a potent multi-targeting kinase inhibitor. DCZ19931 has anti-angiogenic effects on ocular neovascularization. DCZ19931 also inhibits ERK1/2-MAPK and p38-MAPK signaling[1].
Invitro	DCZ19931 (1 nM-10 μM; 24 h) 对人脐静脉内皮细胞 (HUVECs) 无明显的细胞毒性[1]。DCZ19931 (500 nM; 24 h) 抑制 (10 ng/mL; 12 h) VEGFs 诱导的内皮细胞增殖、迁移和成管能力[1]。DCZ19931 (500 nM; 24 h) 通过下调 ICAM-1，表达抑制血管通透性[1]。DCZ19931 (500 nM; 24 h) 降低 HUVECs 中 p-ERK1/2、p-p38 和 p-JNK 的表达水平[1]。DCZ19931 在小鼠脉络膜发芽试验中也显示出抗血管生成作用[1]。 Western Blot Analysis[1] Cell Line:
In Vivo	DCZ19931 (1 μL, 1 μg/μL; 静脉注射; 单剂量) 抑制小鼠氧诱导视网膜病变 (OIR) 模型眼新生血管生成[1].DCZ19931 (2 μL, 1 μg/μL; 静脉注射; 7 d) 无组织毒性，并抑制激光诱导脉络膜新生血管 (CNV) 模型小鼠的眼部新生血管生成[1]。 Animal Model:
Name	DCZ19931
CAS	2789629-84-9
Formula	C26H20F5N3O5
Molar Mass	549.45
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Zhang H, et al. DCZ19931, a novel multi-targeting kinase inhibitor, inhibits ocular neovascularization. Sci Rep. 2022 Dec 13;12(1):21539.

PeptideDB